SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by AspenBio Pharma, Inc. on May 9, 2006. The registrant is a Colorado-based company focused on pharmaceutical development. The report details the completion of a private placement of equity securities and the addition of scientific personnel.
Key Financial Metrics
- Capital Raised: $2,192,000 total from the private placement.
- Shares Issued: 1,565,714 shares of Common Stock.
- Price Per Share: $1.40.
- Investor Type: Accredited investors only.
- Underwriting Fees: No commission was paid on the offering.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the private placement. The offering included $1,428,000 previously announced on April 13, 2006, with the remainder completed on May 9, 2006. Additionally, the company announced the addition of scientific personnel.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds are designated for working capital, new product development, and general corporate purposes.
- Regulatory Status: The shares were issued in reliance on Section 4(2) of the Securities Act of 1933 and Rule 506. They are unregistered and may not be offered or sold in the United States absent registration or an applicable exemption.
- Outlook: The filing does not provide specific financial guidance or forward-looking projections beyond the stated use of funds.
Investor Verification Checklist
- Verify the total number of outstanding shares post-issuance to assess dilution impact.
- Confirm the specific identities of the accredited investors if disclosed in subsequent filings.
- Review the attached press release (Exhibit 99.1) for details on the newly hired scientific personnel.
- Check subsequent filings for the actual deployment of the $2.192 million raised for product development.